CVRX vs. ARAY, OBIO, QIPT, DRTS, PROF, CLPT, DCTH, TELA, RCEL, and ANGO
Should you be buying CVRx stock or one of its competitors? The main competitors of CVRx include Accuray (ARAY), Orchestra BioMed (OBIO), Quipt Home Medical (QIPT), Alpha Tau Medical (DRTS), Profound Medical (PROF), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), TELA Bio (TELA), AVITA Medical (RCEL), and AngioDynamics (ANGO). These companies are all part of the "surgical & medical instruments" industry.
CVRx (NASDAQ:CVRX) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Accuray has a net margin of -4.99% compared to CVRx's net margin of -123.58%. Accuray's return on equity of -44.46% beat CVRx's return on equity.
75.3% of CVRx shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 18.9% of CVRx shares are owned by company insiders. Comparatively, 3.8% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Accuray has higher revenue and earnings than CVRx. Accuray is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.
CVRx has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
CVRx currently has a consensus price target of $16.60, suggesting a potential upside of 115.86%. Accuray has a consensus price target of $8.25, suggesting a potential upside of 422.15%. Given Accuray's stronger consensus rating and higher possible upside, analysts clearly believe Accuray is more favorable than CVRx.
In the previous week, Accuray had 2 more articles in the media than CVRx. MarketBeat recorded 4 mentions for Accuray and 2 mentions for CVRx. CVRx's average media sentiment score of 0.30 beat Accuray's score of 0.29 indicating that CVRx is being referred to more favorably in the media.
Accuray received 315 more outperform votes than CVRx when rated by MarketBeat users. Likewise, 65.67% of users gave Accuray an outperform vote while only 57.14% of users gave CVRx an outperform vote.
Summary
Accuray beats CVRx on 12 of the 18 factors compared between the two stocks.
Get CVRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
